Nataly Tarasenko
Petah Tiqwa, M, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs.
Journal: Journal of visualized experiments : JoVE
Published: January 02, 2023
Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types.
Journal: Cancer letters
Published: January 06, 2022
Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 11, 2021
The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model.
Journal: International journal of molecular sciences
Published: January 23, 2019
Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Journal: Journal of cellular biochemistry
Published: July 18, 2017
AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.
Journal: Investigational new drugs
Published: June 08, 2017
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Journal: Investigational new drugs
Published: December 11, 2016
Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: March 15, 2016
The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Journal: PloS one
Published: August 19, 2015
A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo.
Journal: Biochemical pharmacology
Published: November 24, 2013
A histone deacetylase inhibitory prodrug - butyroyloxymethyl diethyl phosphate - protects the heart and cardiomyocytes against ischemia injury.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: October 06, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026